Safety and efficacy of a continuous infusion, patient controlled antiemetic pump to facilitate outpatient administration of high-dose chemotherapy
|
|
- Morris Marsh
- 6 years ago
- Views:
Transcription
1 Bone Marrow Transplantation, (1999) 24, Stockton Press All rights reserved /99 $ Safety and efficacy of a continuous infusion, patient controlled antiemetic pump to facilitate outpatient administration of high-dose chemotherapy SP Dix, MK Cord, SJ Howard, JL Coon, RJ Belt and RB Geller Blood and Marrow Transplant Program, Oncology and Hematology Associates and Saint Luke s Hospital of Kansas City, Kansas City, MO, USA Summary: We evaluated the combination of diphenhydramine, lorazepam, and dexamethasone delivered as a continuous i.v. infusion via an ambulatory infusion pump with patient-activated intermittent dosing (BAD pump) for prevention of acute and delayed nausea/vomiting in patients receiving high-dose chemotherapy () for peripheral blood progenitor cell (PBPC) mobilization () or prior to autologous PBPC rescue. The BAD pump was titrated to patient response and tolerance, and continued until the patient could tolerate oral antiemetics. Forty-four patients utilized the BAD pump during 66 chemotherapy courses, 34 (52%) for and 32 (48%) for with autologous PBPC rescue. The median number of days on the BAD pump during and was 3 (1 6) and 9 (2 19) days, respectively. Complete overall or complete emesis control occurred on 94% of and 89% of treatment days during chemotherapy administration and 72% and 43%, respectively, following chemotherapy administration. Eighty-three percent of and 55% of treatment days were associated with no nausea. While on the BAD pump, no patient experienced severe toxicity or required hospitalization for management of nausea/vomiting. The BAD pump was safe and effective in minimizing nausea and vomiting associated with, and thus, eliminated the need for hospitalization for management of chemotherapy-induced nausea and vomiting. Keywords: high-dose chemotherapy; autologous peripheral blood progenitor cell transplantation; outpatient BMT; anti-emetic therapy Introduction Historically, patients undergoing blood or marrow transplantation (BMT) have required prolonged hospitalization for administration of high-dose chemotherapy () and recovery from regimen-related toxicities. In 1994, Peters Correspondence: SP Dix, Blood and Marrow Transplant Program, Oncology and Hematology Associates of Kansas City, 4320 Wornall Road, Suite 220, Kansas City, Missouri 64111, USA Received 22 May 1998; accepted 28 January 1999 and colleagues 1 described an outpatient BMT care model utilizing intensive clinic support following inpatient administration of. This approach facilitated early patient discharge and significantly decreased the total number of days of hospitalization associated with BMT. More recently, equipped BMT centers have extended the outpatient care approach to include administration of in the clinic setting. Success of the total outpatient care approach is dependent upon the availability of experienced staff and necessary resources as well as implementation of supportive care strategies designed to minimize morbidity in the outpatient setting. Despite improvements in supportive care strategies, chemotherapy-induced nausea and vomiting continues to be a side-effect causing significant distress to BMT patients and one that could limit the use of outpatient care during administration. In a survey evaluating symptom distress in BMT patients receiving high-dose chemotherapy in the inpatient setting, frequency and severity of nausea were among the symptoms associated with the highest degree of stress upon discharge from hospital. 2 To date, limited data are available on anti-emetic regimens that can be safely and effectively administered to patients receiving in the outpatient setting. Thus, the development of such regimens is essential to help facilitate outpatient administration of during BMT. The objective of this study was to evaluate the safety and efficacy of a combination of three anti-emetics with different mechanisms of anti-emetic action, diphenhydramine (Benadryl, Parke-Davis, Morris Plains, NJ, USA), lorazepam (Ativan, Wyeth-Ayerst, Philadelphia, PA, USA), and dexamethasone (Decadron, Merck, West Point, PA, USA), also called the BAD pump, delivered as a continuous i.v. infusion with patient-controlled i.v. bolus doses, in patients undergoing chemotherapy mobilization () or followed by autologous peripheral blood progenitor cell (PBPC) transplantation in the outpatient setting. Methods Patients were enrolled and evaluated over a 1 year period from October 1996 to October All patients consented to institutional review board approved treatment protocols including assessments of toxicity and supportive care strategies. In order to participate, patients were required to have met routine clinical eligibility criteria to undergo autolog-
2 562 Granisetron 1 mg or Ondansetron 32 mg i.v. and Dexamethasone 10 mg i.v. q 24 h on days of i.v. chemotherapy BAD pump with basal = ml/h with 2 3 ml bolus q 15 min lockout N/V = no N/V = yes no change appropriate use inappropriate use re-evaluate q 24 h and continue BAD pump until at least 24 h after PBPC infusion re-educate patient and caregiver constant N/V intermittent N/V increase basal by 25 50% (max = 0.6 ml/h) increase bolus by 25 50% (max = 6 ml/dose) N/V = no no change N/V = yes individualize or add rescue anti-emetics re-evaluate q 24 h and continue BAD pump until at least 24 h after PBPC infusion and patient able to tolerate oral anti-emetics Additional guidelines: 1 If assessment in outpatient clinic, BMT nurse to make adjustment. If assessment is after hours or on weekend, BMT home health care nurse to make adjustment in conjunction with BMT on-call MD. 2 Options for rescue anti-emetics include: (1) continue to increase basal and/or bolus and titrate to effect; increments must be done in clinic setting; (2) add haloperidol mg p.o. q 6 h; or (3) add prochlorperazine 10 mg p.o.q 6 h Figure 1 Outpatient anti-emetic algorithm: BAD = diphenhydramine 400 mg i.v., lorazepam 16 mg i.v., and dexamethasone 40 mg i.v. in 100 ml D5W non-pvc at ml/h with 2 3 ml bolus q15 min lockout. Doses for each drug as follows: diphenhydramine mg/h with 8 12 mg bolus; lorazepam mg/h with mg bolus; dexamethasone mg/h with mg bolus. ous BMT based on disease status and organ function along with the following criteria to undergo outpatient care during BMT: (1) the patient must have undergone a psychosocial assessment by the BMT social worker with or without additional assessment by the BMT-designated clinical psychologist or psychiatrist; (2) the patient must have an approved caregiver or caregivers available 24 h a day starting at initiation of or ; (3) the patient must have lodging, either an approved home or hotel, within a 30-min driving radius of the BMT center along with transportation; (4) the patient and caregiver must have attended the BMT Caregiver Class and met class objectives prior to initiation of or ; (5) the patient must have insurance benefits for outpatient care during BMT; and (6) the patient must have signed an informed consent to receive or followed by autologous PBPCT in the outpatient setting. Regimens for PBPC mobilization or preparative regimen were selected based on institutional disease-specific protocols. All chemotherapy doses were initiated in the morning in the BMT outpatient clinic. Patients received standard premedications consisting of a serotonin antagonist, ondansetron 32 mg i.v. or granisetron 1 mg i.v., plus dexamethasone 10 mg i.v. each day beginning 30 min before the first dose of chemotherapy. The BAD pump was initiated in the afternoon on the first day of high-dose chemotherapy and administered as outlined in Figure 1. The BAD pump was prepared by mixing diphenhydramine 400 mg i.v., lorazepam 16 mg i.v., and dexamethasone 40 mg i.v. in a total volume of 100 ml D5W in a non-polyvinylchloride bag to minimize adsorption. All patients were initiated at a dose of ml/h continuous basal rate with a 2 3 ml patient-activated bolus option programmed
3 with a 15-min lockout between boluses. Dosing was based on patient weight with patients weighing more than 80 kg initiated at the higher end of the dosing range. The pump was refilled every 48 h or sooner if needed. Dexamethasone was deleted after a maximum duration of 96 h. The pump was continued until at least 24 h after chemotherapy or PBPC infusion and the patient was able to tolerate oral antiemetics. The BAD combination was infused via the Abbott Provider 6000 ambulatory infusion pump (Abbott Laboratories, Abbott Park, IL, USA). Patients and caregivers were instructed on battery alarms and changes, and a back-up set of 9 V batteries were dispensed with each pump. Flumazenil (Romazicon; Roche Laboratories, Nutley, NJ, USA), the benzodiazepine reversing agent, with necessary supplies for administration, was also dispensed at the time of initiation of the pump and kept in the patient s home or hotel room. Patients were assessed daily in the outpatient BMT clinic while on the BAD pump and after discontinuation. After clinic hours, patients were instructed to call the on-call BMT physician or home health care nurse for any problems with the pump or refractory nausea and/or vomiting. The number of emetic episodes (EE) per day was recorded by the nurses while in the clinic. When outside the clinic, caregivers recorded the number of EE on a diary sheet. On the following day, the nurse recorded the total number of EE for each 24-h period in the patient chart. An EE was defined as a single vomit or retch or any number of continuous episodes of vomiting or retching occurring within 1 min of each other. Response per 24 h was categorized as follows: complete overall control = no EE, no nausea, and no rescue medications; complete emesis control = no EE, no rescue medications; major emesis control = 1 2 EE per day. Nausea and other toxicities were also assessed daily and graded based on National Cancer Institute Common Toxicity Criteria. Other data endpoints collected included the duration of the BAD pump, the number of BAD pump dose adjustments required, the name and duration of rescue antiemetics prescribed, and the number of hospitalizations for nausea and/or vomiting. Results Over the 1 year period, the BAD pump was used with a total of 66 high-dose chemotherapy treatment regimens in 44 patients. Demographic information and chemotherapy regimens are outlined in Table 1. In terms of emetogenic potential, all chemotherapy regimens were classified as highly emetogenic based on the Hesketh criteria with the exception of high-dose melphalan which is not included in the Hesketh proposal. 3 Of the 66 treatment regimens, 34 (52%) were for PBPC mobilization and 32 (48%) treatment regimens were for followed by autologous PBPC transplant. All patients received hydration with 1 2 liters overnight on the days of chemotherapy. On cyclophosphamide days, hydration included mesna given as a continuous 24-h infusion at 100% of the cyclophosphamide dose. The initiation dose of the BAD pump was 0.2 ml/h with a 2 ml bolus every 15 min lockout for 49 (74%) of the Table 1 Demographics and results No. of BAD pump courses 66 No. of mobilization courses 34 (52%) (Regimen = cyclophosphamide 4000 mg/m 2 i.v. on day 1, then G-CSF 10 g/kg/d s.c. day 2 or GM-CSF 500 g/d s.c. day 2 to pheresis) No. of with autologous PBPCT courses 32 (48%) Breast CA Cyclophosphamide 2000 mg/m 2 /d days 5, 19 4, 3 Thiotepa 167 mg/m 2 /d days 5, 4, 3 Carboplatin 267 mg/m 2 /d days 5, 4, 3 Multiple myeloma: Melphalan 100 mg/m 2 /d 6 days 3, 2 NHL: Carmustine 300 mg/m 2 /d day 7 3 Cytarabine 100 mg/m 2 bid days 6, 5, 4, 3 Etoposide 100 mg/m 2 bid days 6, 5, 4, 3 Cyclophosphamide 35 mg/kg/d days 6, 5, 4, 3 Other regimen a 4 Initiation dose = 0.2 ml/h with 2 ml bolus 49 (74%) q15 min lockout Initiation dose = 0.3 ml/h with 3 ml bolus 17 (26%) q15 min lockout Median duration of BAD pump during 3 days (1 6) (range) Median duration of BAD pump during 9 days (2 19) (range) No. of BAD courses requiring dose adjustment 17 (26%) No. of BAD courses requiring rescue anti- 5 (7.6%) emetics No. of hospitalization for nausea/vomiting 0 during BAD courses a High-dose combination chemotherapy cyclophosphamide based. treatment courses and 0.3 ml/h with a 3 ml bolus every 15 min lockout for the remaining 17 (26%) of the treatment courses (Table 1). Four patients (9%) did not receive dexamethasone because of a history of diabetes (n = 3) or an allergy (n = 1). During regimens, the median number of days on the BAD pump was 3 days (range 1 6 days). During regimens, the median number of days on the pump was 9 days (range 2 19 days). Of the 66 treatment courses, 57 (86%) had data evaluable for efficacy in preventing nausea and vomiting, 33 regimens and 24 regimens. Nine courses were not evaluable for efficacy due to incomplete or missing data. During, complete overall or complete emesis control occurred on all days of chemotherapy administration in 88% of BAD treatment courses and on all days following chemotherapy administration while on the BAD pump in 64% of courses. During, complete overall or complete emesis control occurred on all days of chemotherapy administration in 75% of BAD treatment courses and on all days following chemotherapy administration while on the BAD pump in 35% of courses. These data are subdivided for complete overall and complete emesis control and depicted graphically in Figure 2. When evaluating treatment days on the BAD pump, 59% and 81% of treatment 563
4 564 % of treatment courses Post CEC COC COC 26/33 (79%) 11/33 (33%) 12/33 (36%) 7/24 (29%) 3/20 (15%) 5/24 (21%) CEC 9/33 (29%) 10/33 (31%) 10/33 (31%) 11/24 (46%) 4/20 (20%) 5/24 (21%) Figure 2 Response rate by treatment course: percentage of patients per phase of treatment course who experienced complete overall control (COC) or complete emesis control (CEC) on all days of treatment course. % of treatment days Post Post MEC CEC COC COC 29/35 (83%) 21/58 (36%) 50/93 (54%) 40/72 (56%) 25/145 (17%) 65/217 (30%) CEC 4/35 (11%) 21/58 (36%) 25/93 (27%) 24/72 (33%) 38/145 (26%) 62/217 (29%) MEC 2/35 (6%) 12/58 (21%) 14/93 (15%) 8/72 (11%) 66/145 (46%) 74/217 (34%) Figure 3 Response rate by treatment days: percentage of treatment days per phase where patient experienced complete overall control, complete emesis control, or major emesis control (MEC). days had complete overall or complete emesis control during and mobilization courses, respectively. Control rates achieved based on treatment days are subdivided for complete overall control, complete emesis control, and major emesis control and depicted graphically in Figure 3. During mobilization, 67% (22/33) of courses were associated with no EE while on the BAD pump. While on the BAD pump during regimens, 38% (9/24) of courses were also associated with no EE on any day, 21% (5/24) with a maximum of one EE per day, and 29% (7/24) with a maximum of two EE per day. During and following, patients experienced no nausea on 83% (29/35) and 36% (21/58) of treatment days, respectively. During and following, patients experienced no nausea on 55% (40/72) and 17% (25/145) of treatment days, respectively. In terms of severity of nausea during mobilization, the maximum nausea grade experienced on any given day while on the BAD pump was grade 0 for 44% of courses, grade I for 35%, grade 2 for 18%, and grade 3 for 3%. During regimens, the maximum nausea grade experienced on any given day while on the BAD pump was grade 0 for 20%, grade 1 for 20%, grade 2 for 40%, and grade 3 for 20%. All patients were evaluated in the outpatient clinic daily; however, no patient required hospitalization for management of refractory nausea and/or vomiting while on the BAD pump. Seventeen of the 66 (25%) treatment courses required a median of one dose adjustment in the BAD pump with 82% of dose adjustments occurring during the treatment courses. The maximum dose delivered was 0.4 ml/h with 4 ml bolus every 15 min lockout and was given to only one patient. No patient required rescue anti-emetics while on the BAD pump during. During, five (16%) BAD treatment courses required the addition of rescue antiemetics (Table 1). In terms of toxicity, patients reported mild (grade I) headache during 12.5% of treatment courses. On at least 1 day on the BAD pump, all patients experienced grade I II depressed levels of consciousness consisting of somnolence or sedation with or without interference in function, but not interfering with activities of daily living. Dexamethasone was discontinued early during four treatment courses secondary to indigestion (n = 2), hiccoughs (n = 1), and restlessness (n = 1). No severe toxicities related to the BAD pump occurred. No pump malfunctions occurred which resulted in inaccurate dosing or administration of the BAD infusion. One patient had the pump replaced three times because of an inability to infuse; however, this was later determined to be a central line problem requiring line replacement. Discussion Given the complexity of BMT and differences in resources available among centers, various models have been developed and implemented to facilitate outpatient care during BMT. The first model to be widely publicized and noted to decrease hospitalization was the model developed at Duke University where the regimen is delivered in the inpatient setting and then patients are discharged to the outpatient setting for supportive care management during neutropenia and the early recovery phase. 1 More recently, certain BMT centers have attempted to expand the outpatient care model to include delivery of high-dose chemotherapy in the outpatient setting. 4 In order to implement this total outpatient care approach, supportive care protocols must be implemented and include management of acute chemotherapy-related toxicity, particularly gastrointestinal complications. While various studies have described successful outpatient management of other BMT-related supportive care issues such as infectious complications, limited data are available describing successful strategies to prevent and manage acute nausea and vomiting associated with delivery of in the outpatient setting. 5 In the Duke University outpatient model, the anti-emetic regimen initially implemented consisted of a continuous infusion of prochlorperazine in combination with lorazepam or other individualized rescue anti-emetics. 1 Following completion of in the inpatient setting, patients were often discharged on continuous or twice daily doses of i.v. ondansetron delivered via an ambulatory infusion pump for management of delayed nausea and vomiting. Miyahara et al 6 evaluated the efficacy of an oral anti-emetic
5 strategy of granisetron 1 mg twice daily combined with lorazepam or other agents as first-line therapy for management of acute and delayed nausea and vomiting in a prospective study conducted in the inpatient setting. The objective of this pilot study was to evaluate the feasibility of outpatient care during and after delivery of the STAMP V preparative regimen followed by autologous bone marrow rescue. Despite aggressive efforts to manage patients with oral medications, Miyahara et al 6 reported that over 40% of patients required a median of 7 days of i.v. anti-emetics, primarily lorazepam, for management of chemotherapyinduced nausea and vomiting. These data suggest a need to develop a strategy incorporating i.v. anti-emetics in order to successfully deliver in the outpatient setting. Meisenberg et al 4 recently published data describing their experience on a subtotal outpatient BMT care model where was administered in the hospital and a total outpatient BMT care model where was administered in the clinic. Meisenberg et al 4 report that most patients received a combination of continuous infusions of lorazepam, prochlorperazine, and diphenhydramine for antiemetic prophylaxis. These authors do not provide specific information on dosing or administration and do not report data on specific response rates to this regimen in terms of management of nausea and vomiting. Of note, no patient in the total outpatient program was admitted for refractory nausea and vomiting. These data are, thus, encouraging and suggest that can be safely administered in the outpatient setting, yet fail to provide descriptive details on outpatient management of -associated nausea and vomiting. In our study, the objective was to evaluate the safety and efficacy of a combination i.v. anti-emetics given as a continuous infusion with patient-activated bolus dosing in patients receiving in the outpatient setting. This evaluation also provides practical and descriptive information to the clinician using such treatment regimens. The combination of diphenhydramine, lorazepam, and dexamethasone, called the BAD pump, was delivered as a very low basal rate with patient-activated, bolus doses, much like a patient-controlled analgesia pump administered for control of acute pain. The drugs used in this combination were selected for their different mechanisms of action against the emetic center and potential to provide a broad scope of antiemetic action. Potential advantages of this regimen include the psychological benefit of patient control by allowing for self-dosing and the relative ease of delivery by using the ambulatory pump. 7 Possible disadvantages include the potential for excess sedation with the use of diphenhydramine and lorazepam, short-term side-effects related to dexamethasone, overuse by the patient, and pump malfunction. In terms of efficacy, we found the BAD pump in combination with standard pre-medications of a serotonin antagonist plus dexamethasone to provide at least comparable efficacy to first-line anti-emetic regimens used with nontransplant, highly emetogenic regimens such as high-dose cisplatin. 8,9 The BAD pump was most effective on days of chemotherapy administration. On days following chemotherapy administration, the BAD pump was less effective in providing complete control; however, it did provide at least major emesis control in the majority of patients. Although limited, other data evaluating anti-emetic prophylaxis consisting of a serotonin antagonist alone during stem cell transplantation report complete or major response rates of 51 58% during the regimen. 10,11 Our response rates were at least comparable to these reports, but more importantly facilitated outpatient admininstration of, the primary goal of this study. In terms of safety, this regimen was not associated with any serious toxicity, despite the continuous use of medications with sedative properties. No patient experienced any serious adverse effect due to overuse or pump malfunction. Patients did experience sedation or somnolence at some time on the pump, but this was easily managed by dose titration and the continued presence of a caregiver for assistance. The ambulatory infusion pumps were associated with only minor maintenance needs, primarily battery changes, once the patient was discharged from the clinic. Routine nursing procedures to minimize potential pump malfunctions such as requiring two nurses to check the settings prior to discharge and daily heparin flushes of the BAD infusion lumen of the central catheter were most likely responsible for the surprisingly low rate of ambulatory infusion pump-related problems. While on the BAD pump, four patients did experience adverse effects presumed to be related to the dexamethasone including indigestion, hiccoughs, and restlessness. These adverse effects resolved upon discontinuation of the dexamethasone, and patients were then able to be effectively controlled on just the combination of diphenhydramine and lorazepam in the pump. No other clinically significant, potentially steroid-related adverse effects were observed. The low rate of steroid-induced adverse effects is most likely related to the short duration of the therapy, but may also have been due to careful patient screening. To minimize adverse effects, patients with diabetes (n = 3) or a previously documented intolerance to steroids (n = 1) did not receive dexamethasone in the anti-emetic pump. Other initial concerns with the use of the BAD pump were the lack of compatibility information available on this combination and the potential for the BAD pump to constantly occupy i.v. access. Although chemical compatibility data are lacking, this combination was physically compatible for at least 48 h based on visual observation. To minimize adsorption of lorazepam to the plastic containers, nonpolyvinyl-chloride containers were used. 12 In addition, dextrose was used as a diluent instead of saline to minimize decomposition of lorazepam. With these concessions to enhance potency of the lorazepam and based on the premise that the combination was titrated to effect, we felt a chemical compatibility test was not warranted in order to proceed with the study objective. In addition to being a safe and effective anti-emetic regimen, our regimen is also less costly than some other combinations implemented during stem cell transplantation. For example, the regimen published by Barbounis et al 11 utilizing a total of 28 i.v. doses of ondansetron 8 mg over an 8- day period is associated with a total drug cost of approximately $1400 based on 1998 average wholesale prices. 12 Our regimen was associated with a comparable response rate and incorporated more drugs, yet costs less than the 565
6 566 regimen of Barbounis et al. Considering drug costs only, our regimen, including granisetron 1 mg i.v. plus dexamethasone 10 mg i.v. daily during chemotherapy for 3 days plus the BAD pump for a median of 9 days, costs approximately $700 for the entire regimen. In addition, our regimen facilitates outpatient administration of and prevents the need for hospitalization, which has the potential to further substantially decrease the overall cost of care during BMT. In summary, we found this combination of diphenydramine, lorazepam, and dexamethasone, the BAD pump, along with a serotonin antagonist plus dexamethasone on days of chemotherapy to be effective in preventing or minimizing nausea and vomiting during chemotherapy-based and with autologous PBPC transplantation. In addition, the safety and effectiveness of this regimen facilitated outpatient care and eliminated the need for hospitalization to administer, as has been the standard of care in most BMT centers. By continuing the BAD pump until the patient could be maintained on oral medication, we were also able to control and eliminate hospitalization for management of delayed nausea and vomiting. Further studies are warranted to evaluate the role of the BAD pump to facilitate outpatient care in other patient populations receiving highly emetogenic chemotherapy regimens. Acknowledgements We are grateful to Keely Hotchkiss RN, and Elaine Stenstrup RN, for their assistance in development and implementation of this research protocol. References 1 Peters WP, Ross M, Vredenburgh JJ et al. The use of intensive clinic support to permit outpatient autologous bone marrow transplantation for breast cancer. Semin Oncol 1994; 21 (Suppl. 7): Lawrence CC, Gilbert CJ, Peters WP. Evaluation of symptom distress in a bone marrow transplant outpatient environment. Ann Pharmacother 1996; 30: Hesketh PJ, Kris MG, Grunberg SM et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997; 15: Meisenberg BR, Miller WE, McMillan R et al. Outpatient high-dose chemotherapy with autologous stem-cell rescue for hematologic and nonhematologic malignancies. J Clin Oncol 1997; 15: Gilbert C, Meisenbert B, Vrendenburgh J et al. Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support. J Clin Oncol 1994; 12: Miyahara TT, Dix SP, Devine SM et al. Evaluation of supportive care guidelines for monitoring breast cancer bone marrow transplant patients in the outpatient setting. Blood 1995; 86 (Suppl. 1): 213a (Abstr.). 7 Thomas V, Heath M, Rose D et al. Psychological characteristics and the effectiveness of patient-controlled analgesia. Br J Anaesthesia 1995; 74: Hesketh PJ, Harvey WH, Harket WG et al. A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of emesis of high-dose cisplatin-induced emesis. J Clin Oncol 1994; 12: Kris MG, Pendergrass KB, Navari R et al. Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone. J Clin Oncol 1997; 15: Okamoto S, Takahaski S, Tanosaki R et al. Granisetron in the prevention of vomiting induced by conditioning for stem cell transplantation: a prospective randomized study. Bone Marrow Transplant 1996; 17: Barbounis V, Koumakis G, Vassilomanolakis M et al. A phase II study of ondansetron as antiemetic prophylaxis in patients receiving high-dose polychemotherapy and stem cell transplantation. Support Care Cancer 1995; 3: Trissel LA. Handbook on Injectable Drugs. American Society of Health-System Pharmacists: Bethesda, MD, 1996, pp
Updates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017
Updates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017 MELISSA C. MACKEY, PHARMD, BCPS, BCOP ONCOLOGY CLINICAL PHARMACIST DUKE UNIVERSITY HOSPITAL AUGUST 5, 2017 Objectives Review risk factors
More informationDrug: Aprepitant (Emend ) Date of Review: 4/01/10
CAMBRIDGESHIRE JOINT PRESCRIBING GROUP Business Case Evaluation and Recommendation Document Drug: Aprepitant (Emend ) Date of Review: 4/01/10 Business Case Decision and date: DOUBLE RED, 20 January 2010
More informationClinical Policy: Nabilone (Cesamet) Reference Number: ERX.NPA.35 Effective Date:
Clinical Policy: (Cesamet) Reference Number: ERX.NPA.35 Effective Date: 09.01.17 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationUsing a Simple Diary for Management of Nausea and Vomiting During Chemotherapy
Using a Simple Diary for Management of Nausea and Vomiting During Chemotherapy Problem identification Nausea and vomiting (N&V) are frequent complications following chemotherapy, even when taking 5-HT3
More informationGuideline Update on Antiemetics
Guideline Update on Antiemetics Clinical Practice Guideline Special Announcements Please check www.asco.org/guidelines/antiemetics for current FDA alert(s) and safety announcement(s) on antiemetics 2 Introduction
More informationTRANSPARENCY COMMITTEE OPINION. 31 January Date of marketing authorisation: 22 March 2005 (centralised marketing authorisation)
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 31 January 2007 ALOXI 250 µg solution for injection B/1 CIP 375,482-8 Applicant: THERABEL LUCIEN PHARMA palonosetron
More informationClinical Policy: Ondansetron (Zuplenz) Reference Number: CP.PMN.45 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Zuplenz) Reference Number: CP.PMN.45 Effective Date: 09.01.06 Last Review Date: 02.19 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationClinical Policy: Dolasetron (Anzemet) Reference Number: ERX.NPA.83 Effective Date:
Clinical Policy: (Anzemet) Reference Number: ERX.NPA.83 Effective Date: 09.01.18 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Anzemet) Reference Number: CP.PMN.141 Effective Date: 09.01.06 Last Review Date: 08.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
More informationDefining the Emetogenicity of Cancer Chemotherapy Regimens: Relevance to Clinical Practice
Defining the Emetogenicity of Cancer Chemotherapy Regimens: Relevance to Clinical Practice PAUL J. HESKETH St. Elizabeth s Medical Center, Boston, Massachusetts, USA Key Words. Chemotherapy Emesis Emetogenicity
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Cesamet) Reference Number: CP.PMN.160 Effective Date: 11.16.16 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationPrevention CINV (highly emetogenic) Prevention PONV
Reviews/Evaluations 5-Hydroxytryptamine3 (5-HT3) Receptor Antagonists Generic Name Brand Name Manufacturer Dolasetron Anzemet Aventis Granisetron Kytril Roche Ondansetron Zofran GlaxoSmithKline I. FDA
More informationStudent Project PRACTICE-BASED RESEARCH
Pharmacist-Driven Management of Chemotherapy Induced Nausea and Vomiting in Hospitalized Adult Oncology Patients. A Retrospective Comparative Study Ramy Elshaboury, PharmD 1 and Kathleen Green, PharmD,
More informationPing-Tsung Chen, MD; Chuang-Chi Liaw, MD
Original Article 167 Intravenous Ondansetron plus Intravenous Dexamethasone with Different Ondansetron Dosing Schedules during Multiple Cycles of Cisplatin-based Chemotherapy Ping-Tsung Chen, MD; Chuang-Chi
More informationMASCC Guidelines for Antiemetic control: An update
MASCC / ISOO 17 th International Symposium Supportive Care in Cancer June 30 July 2, 2005 / Geneva, Switzerland MASCC Guidelines for Antiemetic control: An update Sussanne Börjeson, RN, PhD Linköping University,
More informationDrug Name: Aprepitant (Emend ) Manufacturer: Merck & Co., Inc.
Drug Name: Aprepitant (Emend ) Manufacturer: Merck & Co., Inc. Pharmacology: Aprepitant (previously known as MK-0839 and L-754030) is a new molecular entity that is the first in a new therapeutic class,
More informationGUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION
GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY More than half of all cancer patients experience nausea or vomiting during the course of their treatment. If nausea or vomiting becomes severe enough,
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Antiemetic Therapy Table of Contents Coverage Policy... 1 General Background... 6 Coding/Billing Information... 8 References... 8 Effective Date... 1/1/2018
More informationWhy Patients Experience Nausea and Vomiting and What to Do About It
Why Patients Experience Nausea and Vomiting and What to Do About It Rebecca Clark-Snow, RN, BSN, OCN The University of Kansas Cancer Center Westwood, Kansas Multiple Roles for Supportive Care in Cancer
More informationNausea and Vomiting Team. Outcome: Nausea and Vomiting. Scope of the Problem. Definition: Nausea
Nausea and Vomiting: The Continuing Battle to Improve Outcomes Jan Tipton, MSN, RN, AOCN Oncology CNS Medical University of Ohio Toledo, Ohio jtipton@meduohio.edu Nausea and Vomiting Team Jan Tipton, MSN,
More informationAntiemetic Prophylaxis with Ondansetron and Methylprednisolone vs Metoclopramide and Methylprednisolone in Mild and Moderately Emetogenic Chemotherapy
218 Journal of Pain and Symptom Management Vol. 18 No. 3 September 1999 Original Article Antiemetic Prophylaxis with Ondansetron and Methylprednisolone vs Metoclopramide and Methylprednisolone in Mild
More informationATTUALITÀ NEL CONTROLLO DELL EMESI
ATTUALITÀ NEL CONTROLLO DELL EMESI Dr Claudio Lotesoriere Dipartimento di Oncoematologia S.C. di Oncologia Medica P.O. San G. Moscati TARANTO email oncologia.taranto@gmail.com Types of CINV: Definitions
More information9/3/2014. Conflict of Interest Disclosures. Learning Objectives. Definitions of Nausea/Vomiting. Definitions of Nausea/Vomiting
Conflict of Interest Disclosures LeAnn B. Norris Teva Pharmaceuticals Last Chance Webinar 2014 Oncology Supportive Care LeAnn B. Norris, PharmD, BCPS, BCOP Assistant Professor South Carolina College of
More informationOral Granisetron for the Prevention of Acute Late Onset Nausea and Vomiting in Patients Treated with Moderately Emetogenic Chemotherapy
Oral Granisetron for the Prevention of Acute Late Onset Nausea and Vomiting in Patients Treated with Moderately Emetogenic Chemotherapy CARL J. FRIEDMAN, a HOWARD A. BURRIS III, b KAREN YOCOM, a LINDA
More informationDERBY-BURTON LOCAL CANCER NETWORK FILENAME R-IVE.DOC CONTROLLED DOC NO: HCCPG B53 CSIS Regimen Name: R-IVE. R-IVE Regimen
R-IVE Regimen Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication Relapsed/ refractory
More informationR-ICE Regimen- Rituximab, Etoposide, Ifosfamide (with MESNA), Carboplatin (+ Depocyte if CNS involvement)
R-ICE Regimen- Rituximab, Etoposide, Ifosfamide (with MESNA), Carboplatin (+ Depocyte if CNS involvement) Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case
More informationManagement of Nausea and Vomiting
June 01, 2015 By Rudolph M. Navari, MD, PhD, FACP [1] Although marked progress in controlling chemotherapy-induced emesis has occurred over the past 25 years, nausea and vomiting remain among the most
More informationSAALT3W Sarcoma Dr. Meg Knowling. Protocol Code Tumour Group Contact Physician
BCCA Protocol Summary for Etoposide, Ifosfamide-Mesna (SAIME) Alternating with vincristine, DOXOrubicin and Cyclophosphamide (with or without Mesna)(SAVAC or SAVACM) with Filgrastim Support at a THREE
More informationChemotherapy-induced nausea and vomiting (CINV)
At a Glance Practical Implications e54 Author Information e57 Full text and PDF 5-HT3 Receptor Antagonist Effects in Cancer Patients With Multiple Risk Factors Original Research Claudio Faria, PharmD,
More informationMobilization & Pre-Transplant Conditioning Regimens
Transplant Process & Pre-Transplant Conditioning Regimens (auto patients only) 30 days before BMT (allo donors) 5 days before BMT Conditioning (auto AND allo patients) Transplant A technique used to increase
More informationGuidelines for the Use of Anti-Emetics with Chemotherapy
Guidelines for the Use of Anti-Emetics with The purpose of this document is to provide guidance on the rational use of anti-emetics for prevention and treatment of chemotherapy-induced nausea and vomiting
More informationGOOVIPPC. Protocol Code: Gynecology. Tumour Group: Paul Hoskins. Contact Physician: James Conklin. Contact Pharmacist:
BCCA Protocol Summary for Primary Treatment of Stage III less than or equal to 1 cm Visible Residual Invasive Epithelial Ovarian Cancer or Stage I Grade 3 or Stage II Grade 3 Papillary Serous Ovarian Cancer
More informationPrevention of Antineoplastic Medication induced Nausea and Vomiting in Pediatric Cancer Patients
Prevention of Antineoplastic Medication induced Nausea and Vomiting in Pediatric Cancer Patients Done by :Meznah Zaid Al-Mutairi Pharm.D Candidate PNU University College of Pharmacy Introduction Nausea
More informationADULT Updated: September 4, 2018
Updated: September 4, 2018 Regimen Reference Order ARIA: LYMP [R-CHOP alt. R-DHAP] Planned Course: Indication for Use: Every 21 days for 6 cycles (R-CHOP given on cycles 1, 3 and 5; R-DHAP given on cycles
More informationANTIEMETIC GUIDELINES: MASCC/ESMO
Open Issues for CINV Do we reliably measure that? Do we control nausea optimally? Are guidelines useful for oral therapies related nausea and vomiting? Breakthrough and refractory nausea and vomiting:
More informationManaging Adverse Events in the Cancer Patient. Learning Objectives. Chemotherapy-Induced Nausea/Vomiting
Managing Adverse Events in the Cancer Patient Lisa A Thompson, PharmD, BCOP Assistant Professor University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Learning Objectives Describe
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Kytril, Sancuso, Sustol) Reference Number: CP.PMN.74 Effective Date: 11.01.16 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important
More informationChemotherapy Induced Nausea and Vomiting
Chemotherapy Induced Nausea and Vomiting Aminah Jatoi, M.D. Professor of Oncology Mayo Clinic Rochester, Minnesota April 27, 2017 clinical and biologic fundamentals of chemotherapy induced nausea and vomiting
More informationMATRIX (Methotrexate, Cytarabine, Thiotepa and Rituximab)
MATRIX (Methotrexate, Cytarabine, Thiotepa and Rituximab) Indication First line treatment of primary CNS lymphoma. ICD-10 codes Codes with a prefix C85 Regimen details Day Drug Dose Route 1 and 6 Rituximab
More informationWest of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting
West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting Definitions Acute nausea and vomiting Delayed nausea and vomiting Anticipatory nausea and vomiting Initial
More informationESMO HIGHLIGHTS SUPPORTIVE AND PALLIATIVE CARE
ESMO 2016 - HIGHLIGHTS SUPPORTIVE AND PALLIATIVE CARE FLORIAN SCOTTE Cancer Department Supportive Care in Cancer Unit Georges Pompidou European Hospital Paris France esmo.org DISCLOSURE SLIDE Consultant
More informationInternational Symposium on Supportive Care in Cancer, MASCC/ISOO 2013, Berlin, Germany. What was hot at MASCC/ISOO Annual Meeting this year?
International Symposium on Supportive Care in Cancer, MASCC/ISOO 2013, Berlin, Germany What was hot at MASCC/ISOO Annual Meeting this year? Supportive Care Makes Excellent Cancer Care Possible. This slogan
More informationReview Article Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting
Hindawi Publishing Corporation BioMed Research International Volume 2015, Article ID 595894, 6 pages http://dx.doi.org/10.1155/2015/595894 Review Article Treatment of Breakthrough and Refractory Chemotherapy-Induced
More informationStudy No: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationBCCA Protocol Summary for Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck Cancer Using Fluorouracil and Platinum
BCCA Protocol Summary for Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck Cancer Using Fluorouracil and Platinum Protocol Code: Tumour Group: Contact Physician: HNAVFUP Head and Neck
More informationBMTCN REVIEW COURSE PRE-TRANSPLANT CARE
BMTCN REVIEW COURSE PRE-TRANSPLANT CARE Jennifer Shamai MS, RN, AOCNS, BMTCN Professional Practice Leader Department of Clinical Practice And Professional Education Click How to edit the Master Experts
More informationBRLAACDT. Protocol Code. Breast. Tumour Group. Dr. Karen Gelmon. Contact Physician
BCCA Protocol Summary for Treatment of Locally Advanced Breast Cancer using DOXOrubicin and Cyclophosphamide followed by DOCEtaxel and Trastuzumab (HERCEPTIN) Protocol Code Tumour Group Contact Physician
More informationAntiemetics in chemotherapy
Antiemetics in chemotherapy Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Directorate & Speciality Date of submission Date
More informationIvyspring International Publisher. Introduction. Journal of Cancer 2017, Vol. 8. Abstract
1371 Ivyspring International Publisher Research Paper Journal of Cancer 2017; 8(8): 1371-1377. doi: 10.7150/jca.17102 Antiemetic Effectiveness and Cost-Saving of Aprepitant plus Granisetron Is Superior
More informationPERUGIA INTERNATIONAL CANCER CONFERENCE VII MULTINATIONAL ASSOCIATION FOR SUPPORTIVE CARE IN CANCER
June 2004 PERUGIA INTERNATIONAL CANCER CONFERENCE VII MULTINATIONAL ASSOCIATION FOR SUPPORTIVE CARE IN CANCER CONSENSUS CONFERENCE ON ANTIEMETIC THERAPY PERUGIA, March 29-31, 2004 DELAYED EMESIS WORKING
More informationELIGIBILITY: small cell or neuroendocrine cancer (pure or mixed) administration of this protocol is restricted to BCCA Cancer Centres
BCCA Protocol Summary for Treatment of Small Cell or Neuroendocrine Carcinoma of Gynecologic System Origin using PACLitaxel, CISplatin, Etoposide and CARBOplatin with Radiation (GO 95 02) Protocol Code:
More informationLYIVAC (Magrath B) + R (rituximab) [To be used after LYCODOX-M (Magrath A) + R]
Page 1 of 7 PPO FOR THE TREATMENT OF BURKITT LYMPHOMA AND LEUKEMIA LYIVAC (Magrath B) + R (rituximab) [To be used after LYCODOX-M (Magrath A) + R] DAY DATE CHEMOTHERAPY 1 Start signature sheet and prednisolone
More informationOncology Nursing Society Registry in Collaboration with CE City 2015 Performance Measure Specifications
1 ONSQIR 1 Non-PRQS Measure Oncology Nursing Society Registry in Collaboration with CE City 2015 Performance Measure Specifications Performance Measure Name: Symptom Assessment 1-o1a Symptom Assessment
More informationThalidomide for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy
Thalidomide for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy Geng Song, Qian He, Fanfan Li, and Nianfei Wang Department of Oncology, The Second Affiliated
More informationRituximab, Gemcitabine, Dexamethasone and Cisplatin RGDP Regimen
Rituximab, Gemcitabine, Dexamethasone and Cisplatin RGDP Regimen Available for Routine Use in Burton in-patient N/A Derby in-patient Burton day-case Derby day-case Burton outreach chemotherapy clinic N/A
More informationThe incidence of chemotherapy-induced emesis is difficult to determine, because the cause is likely to be multifactorial and include factors such as
Pediatric Hematology and Oncology, 21: 227 235, 2004 Copyright C Taylor & Francis Inc. ISSN: 0888-0018 print / 1521-0669 online DOI: 10.1080/08880010490427351 SINGLE-DOSE ORAL GRANISETRON VERSUS MULTIDOSE
More informationTIP Paclitaxel, Ifosfamide and Cisplatin
Systemic Anti Cancer Treatment Protocol TIP Paclitaxel, Ifosfamide and Cisplatin PROTOCOL REF: MPHATIPGC (Version No: 1.0) Approved for use in: Second line treatment of germ cell tumours Dosage: Drug Dosage
More informationCHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING Jennifer Shamai MS, RN, AOCNS, BMTCN Professional Practice Leader Department of Clinical Practice And Professional Education Click How to the edit Experts Master
More informationSubject: Fosnetupitant-Palonosetron (Akynzeo) IV
09-J3000-01 Original Effective Date: 06/15/18 Reviewed: 05/09/18 Revised: 01/01/19 Subject: Fosnetupitant-Palonosetron (Akynzeo) IV THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION,
More informationPediatric Trials 23/04/2018. Disclosures. Nausea and Vomiting Control in Adults and Children: Mind the Gap! Learning Objectives
Nausea and Vomiting Control in Adults and Children: Mind the Gap! Disclosures No relevant conflicts of interest Lee Dupuis, RPh, PhD May 5, 2018 2 Learning Objectives At the end of this presentation, attendees
More informationSupportive Care for Patients with Cancer
3:15pm - 4:15pm: Breakout 4 - Oncology Option A: Supportive Care for Patients with Cancer ACPE UAN 0107-0000-10-021-L01-P 0.1 CEU/1.0 Hr. Activity Type: Application-Based Program Objectives for Pharmacists:
More informationSubject: NK-1 receptor antagonist injectable therapy (Emend, Cinvanti, Varubi )
09-J2000-60 Original Effective Date: 06/15/16 Reviewed: 04/11/18 Revised: 01/01/19 Subject: NK-1 receptor antagonist injectable therapy (Emend, Cinvanti, Varubi ) THIS MEDICAL COVERAGE GUIDELINE IS NOT
More informationCorporate Medical Policy
Antiemetic Injection Therapy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: antiemetic_injection_therapy 5/2015 3/2017 3/2018 3/2017 Description of Procedure
More informationGuidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients
Guidelines on Chemotherapy-induced Nausea Vomiting in Pediatric Cancer Patients COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive Care Endorsed Guidelines. DISCLAIMER For
More informationDelayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only)
Support Care Cancer (2011) 19 (Suppl 1):S57 S62 DOI 10.1007/s00520-010-1039-y SPECIAL ARTICLE Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only) Fausto Roila & David
More informationEuropean Medicines Agency
European Medicines Agency SCIENTIFIC DISCUSSION 1. Introduction Emend is an oral substance P, aka human neurokinin 1 (NK-1)-receptor antagonist. Mammalian tachykinin substance P (SP) that binds to the
More informationChemotherapy Induced Nausea and Vomiting (CINV) Anti-emetic Guidelines
North of England Cancer Network Chemotherapy Induced Nausea and Vomiting (CINV) Anti-emetic Guidelines Adult Oncology & Haematology Quality and safety for every patient every time For more information
More informationSupportive care session 1:
Board review in oncology pharmacy 2013 Managing Disease or Treatment Related Complication Supportive care session 1: Chemotherapy induced-nausea and vomiting Suthan Chanthawong, B. Pharm, RPh. Objectives
More informationR-IDARAM. Dexamethasone is administered as an IV infusion in 100mL sodium chloride 0.9% over 30 minutes.
R-IDARAM Indication Secondary CNS lymphoma ICD-10 codes Codes with a prefix C85 Regimen details Day Drug Dose Route 1 Rituximab 375mg/m 2 IV infusion 1 Methotrexate 12.5mg Intrathecal 1 Cytarabine 70mg
More informationSatisfactory Analgesia Minimal Emesis in Day Surgeries. (SAME-Day study) A Randomized Control Trial Comparing Morphine and Hydromorphone
Satisfactory Analgesia Minimal Emesis in Day Surgeries (SAME-Day study) A Randomized Control Trial Comparing Morphine and Hydromorphone HARSHA SHANTHANNA ASSISTANT PROFESSOR ANESTHESIOLOGY MCMASTER UNIVERSITY
More informationCAR-T. Subrena Powell RN, MSN, BMTCN
CAR-T Subrena Powell RN, MSN, BMTCN Objectives Discuss the treatment timeline of a patient receiving CAR-T therapy Describe the side effects and management of symptoms of CAR-T therapy Treatment Schema
More informationPrevention and Management of cancer disease and of chemo-and radiotherapyinduced nausea and vomiting
Prevention and Management of cancer disease and of chemo-and radiotherapyinduced nausea and vomiting Focusing on the updated MASCC/ESMO guidelines Karin Jordan Department of Hematology and Oncology, University
More informationVI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies:
VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Incidence: The incidence of acute and delayed N&V was investigated in highly and moderately emetogenic
More informationBRAJACTT. Protocol Code. Breast. Tumour Group. Dr. Karen Gelmon. Contact Physician
BC Cancer Protocol Summary for Adjuvant Therapy for Breast Cancer using DOXOrubicin and Cyclophosphamide followed by PACLitaxel and Trastuzumab (HERCEPTIN) Protocol Code Tumour Group Contact Physician
More informationPractical Considerations in Multiple Myeloma: Optimizing Therapy With New Proteasome Inhibitors
Welcome to Managing Myeloma. My name is Dr. Donald Harvey. I am Director of Phase 1 Clinical Trials Section and an Associate Professor in Hematology, Medical Oncology, and Pharmacology at the Winship Cancer
More informationAntiemetics: Guidelines, Interactions and more.
Antiemetics: Guidelines, Interactions and more. Chemotherapy-induced side effects -the patient s view Loss of hair The thought of coming for chemo Affects family/partner Affects work/home duties Jude Lees
More informationR-GDP: Rituximab, Gemcitabine, Dexamethasone &Cisplatin
: Rituximab, Gemcitabine, Dexamethasone &Cisplatin INDICATION Relapsed or refractory Hodgkin and non-hodgkin lymphoma. Omit Rituximab for patients with Hodgkin Lymphoma or high grade T cell non-hodgkin
More informationVIP (Etoposide, Ifosfamide and Cisplatin)
VIP (Etoposide, Ifosfamide and Cisplatin) Indication First line treatment for metastatic seminoma, non seminoma or combined tumours where bleomycin is contra-indicated. Usually used for patients with intermediate
More informationClinical Policy: Aprepitant (Emend) Reference Number: CP.PMN.19 Effective Date: 11/06 Last Review Date: 08/17
Clinical Policy: (Emend) Reference Number: CP.PMN.19 Effective Date: 11/06 Last Review Date: 08/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationDERBY-BURTON LOCAL CANCER NETWORK FILENAME ESHAP.DOC CONTROLLED DOC NO: HCCPG B44. ESHAP Regimen
ESHAP Regimen Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication Relapsed/ refractory
More information(30689) PROT Pain PCA Adult Patient Controlled Analgesia
Diagnosis Allergies Nursing Assess and Document PCA: 1. Assess and document pain rating, sedation level and respiratory rate every 2 hours; assess and document pain rating, sedation level and respiratory
More informationSUBCUTANEOUS Bortezomib + Thalidomide +Dexamethasone Available for Routine Use in
SUBCUTANEOUS Bortezomib + Thalidomide +Dexamethasone Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby
More informationOriginal. Key words : breast cancer, chemotherapy-induced nausea and vomiting, quality of life, Functional Living Index Emesis
Showa Univ J Med Sci 30 2, 285 296, June 2018 Original The Impact on Quality of Life of Highly Effective Antiemetic Therapy among Breast Cancer Patients Receiving Anthracycline Plus Cyclophosphamide-based
More informationCisplatin and Pemetrexed (NSCLC, mesothelioma)
Cisplatin and Pemetrexed (NSCLC, mesothelioma) Indication First-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) if the histology of the tumour has been confirmed as
More informationSetting The setting was secondary care. The economic study was carried out in the USA.
The effect of timing of ondansetron administration on its efficacy, cost-effectiveness, and cost-benefit as a prophylactic antiemetic in the ambulatory setting Tang J, Wang B G, White P F, Watcha M F,
More informationOverview of the neurokinin-1 receptor antagonists
Editorial Page 1 of 6 Overview of the neurokinin-1 receptor antagonists Rudolph M. avari Division of Hematology Oncology, School of Medicine, University of Alabama Birmingham, Birmingham, AL, USA Correspondence
More informationGemcitabine, Dexamethasone and Cisplatin GDP Regimen
Gemcitabine, Dexamethasone and Cisplatin GDP Regimen Available for Routine Use in Burton in-patient N/A Derby in-patient Burton day-case Derby day-case Burton outreach chemotherapy clinic N/A Derby outreach
More information(R) CHOEP. May be used for stage IA - IV Diffuse Large B Cell non-hodgkin lymphoma in combination with rituximab.
(R) CHOEP Indication Treatment of stage IA - IV T cell non-hodgkin lymphoma as an alternative to CHOP in younger, fitter patients with normal LDH level. May be used for stage IA - IV Diffuse Large B Cell
More informationBCCA Protocol Summary for Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin and Cyclophosphamide and DOCEtaxel
BCCA Protocol Summary for Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin Cyclophosphamide DOCEtaxel Protocol Code Tumour Group Contact Physician BRAJFECD Breast Dr. Stephen Chia ELIGIBILITY:
More informationBC Cancer Protocol Summary for the Maintenance Therapy of Multiple Myeloma Using Bortezomib for Patients with the High-Risk Chromosome Abnormality
BC Cancer Protocol Summary for the Maintenance Therapy of Multiple Myeloma Using Bortezomib for Patients with the High-Risk Chromosome Abnormality Protocol Code Tumour Group Contact Physician MYBORMTN
More informationMOLECULAR AND CLINICAL ONCOLOGY 2: , 2014
MOLECULAR AND CLINICAL ONCOLOGY 2: 375-379, 2014 Palonosetron exhibits higher total control rate compared to first generation serotonin antagonists and improves appetite in delayed phase chemotherapy induced
More informationManagement of chemotherapyinduced nausea and vomiting
p h a r m a c o t h e r a p y Management of induced nausea and vomiting Authors Key words F. Van Ryckeghem and S. Van Belle Antiemetic therapy,, prevention Summary Chemotherapy-induced nausea and vomiting
More informationJob title: Consultant Pharmacist/Advanced Practice Pharmacist
Title : Guidelines for the Use of Antiemetics Purpose: To provide trust-wide guidance on the safe and effective use of antiemetics for the prevention and treatment of chemotherapy and radiotherapy induced
More informationULYRICE. Protocol Code. Lymphoma. Tumour Group. Dr. Laurie Sehn. Contact Physician
BCCA Protocol Summary for the Treatment of Relapsed or Refractory Advanced Stage Aggressive B-Cell Non-Hodgkin s Lymphoma with Ifosfamide, CARBOplatin, Etoposide and rituximab Protocol Code Tumour Group
More informationBRAJACTTG. Protocol Code. Breast. Tumour Group. Dr. Karen Gelmon. Contact Physician
BC Cancer Protocol Summary for Adjuvant Therapy for Breast Cancer Using Dose Dense Therapy: DOXOrubicin and Cyclophosphamide Followed by PACLitaxel and Trastuzumab (HERCEPTIN) Protocol Code Tumour Group
More informationDoxorubicin and Ifosfamide Sarcoma
Systemic Anti Cancer Treatment Protocol Doxorubicin and Ifosfamide Sarcoma PROTOCOL REF: MPHADOXIFO (Version No:.0) Approved for use in: Soft tissue sarcoma Dosage: Drug Dosage Route Frequency Doxorubicin
More informationA Comparison of Oral Ondansetron and Intravenous Granisetron for the Prevention of Nausea and Emesis Associated with Cisplatin-Based Chemotherapy
A Comparison of Oral Ondansetron and Intravenous Granisetron for the Prevention of Nausea and Emesis Associated with Cisplatin-Based Chemotherapy JESSE I. SPECTOR, a ERIC P. LESTER, b ERIC M. CHEVLEN,
More informationBRAVTPCARB. Protocol Code: Breast. Tumour Group: Dr. Karen Gelmon. Contact Physician:
BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab (HERCEPTIN), PACLitaxel and CARBOplatin as First-Line Treatment for Advanced Breast Cancer Protocol Code: Tumour
More informationManagement of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients
Management of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients By Zahra Shaghaghi, Pharm-D, BCOP, PhC Prepared for 2018 NMSHP Balloon Fiesta Symposium Goals and Objectives: Describe
More information